跳转至内容
Merck
CN

CS1060

SensiZyme BACE1 Activity Assay Kit

sufficient for 96 multiwell tests

别名:

β-Secretase, β-site APP-cleaving enzyme

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


usage

sufficient for 96 multiwell tests

shipped in

dry ice

storage temp.

−20°C

Gene Information

human ... BACE1(23621)

General description

BACE1 (β-secretase or beta-site APP-cleaving enzyme) and γ-secretase are proteases that cleave the amyloid precursor protein (APP) to produce amyloid beta peptide (Aβ). The accumulation of Aβ in the brain is believed to be a primary cause for the progression of Alzheimer′s disease. Knockout studies show that BACE1 is critical for Aβ generation. Transgenic mice lacking BACE1 do not produce Aβ, but show an otherwise normal phenotype with no detrimental effects on viability or morphology. This raises the possibility that therapeutic BACE1 inhibition could be accomplished without major toxicity.

Application

The BACE1 Activity Assay Kit provides all the reagents required for highly sensitive detection of BACE1 activity in cell extracts, cell culture media, tissue extracts, and purified enzyme preparations, and also for inhibitor screening. The protease activity measurement is based on a multistep series of reactions. This assay is sensitive and specific. The enhanced sensitivity is achieved by the signal amplification via the chain reaction. The specificity is achieved by both the immunochemical isolation of the BACE1 enzyme from the extract by specific antibodies bound to the 96-well plate, and the use of an enzyme substrate (Substrate A) containing a BACE1 specific cleavage site.


仅试剂盒组分

产品编号
说明

  • Assay Bufer 6 mL

  • Wash Buffer 80 mL

  • BACE1 Standard 25 μL

  • Substrate A (proenzyme) 10x 500 μL

  • Substrate B 50 μL

  • DTT 400 μL

  • Anti-BACE1 coated 96-well plate 1 ea

pictograms

Corrosion

signalword

Danger

hcodes

Hazard Classifications

Eye Dam. 1 - Skin Irrit. 2

存储类别

10 - Combustible liquids

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容


Latha Devi et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 37(2), 434-444 (2011-09-09)
Increasing evidence suggests that reductions in brain-derived neurotrophic factor (BDNF) and its receptor tyrosine receptor kinase B (TrkB) may have a role in the pathogenesis of Alzheimer's disease (AD). However, the efficacy and safety profile of BDNF therapy (eg, gene
S L Roberds et al.
Human molecular genetics, 10(12), 1317-1324 (2001-06-15)
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by accumulation of amyloid plaques and neurofibrillary tangles in the brain. The major components of plaque, beta-amyloid peptides (Abetas), are produced from amyloid precursor protein (APP) by the activity of beta- and
Lina Adwan et al.
Neuropharmacology, 79, 596-602 (2014-01-28)
Environmental exposure to lead (Pb) early in life results in a latent upregulation of genes and products associated with Alzheimer's disease (AD), particularly the plaque forming protein amyloid beta (Aβ). Furthermore, animals exposed to Pb as infants develop cognitive decline